Increased expression of neutrophil gelatinase-associated lipocalin receptor by interleukin-1β in human mesangial cells via MAPK/ERK activation

Neutrophil gelatinase-associated lipocalin (NGAL), one of the most promising next-generation biomarkers in clinical nephrology, has received extensive attention. However, the basic role of its receptor (NGALR) remains unclear. Here, we have assessed the expression pattern of NGALR in injured glomeruli and explored the possible mechanism of the NGALR involvement in inflammation in human mesangial cells (H MC). The expression pattern of NGALR was detected by immunohistochemistry in biopsy samples of 93 glomerulonephritis patients and healthy controls, and the regulation of NGALR by the proinflammatory cytokines, TGF-beta 1, TNF-alpha and IL-1 beta in HMC was analyzed by real-time PCR and Western blotting. NGALR was found to be expressed in glomeruli. Its expression was significantly higher in acute proliferative glomerulonephritis and lupus nephritis than that in other types of glomerulonephritis or healthy kidney tissues. In in vitro experiments, both mRNA and protein levels of NGALR were dramatically induced by treatment of IL-1 beta, whereas TGF-beta 1 or TNF-a did not have the same effect. Furthermore, it was shown that the IL-1 beta-induced NGALR expression is mediated via the MAPK/ERK signaling pathway by using pharmacological inhibitors. Interestingly, the basal mRNA levels of NGAL detected in HMC, could be induced by IL-1 beta. However, NGAL protein could not be detected, even with IL-1 beta treatment. The ability of HMC to express NGAL protein was ascertained by exogenous administration of NGAL. In conclusion, the data show that NGALR is differentially expressed in human glomerular disease and is significantly up-regulated by IL-1 beta in HMC via MAPK/ERK activation. Furthermore, exogenous NGAL can be uptaken into HMC.